Cutaneous leukocytoclastic vasculitis associated with erlotinib treatment: A case report and review of the literature
- 19 November 2018
- journal article
- review article
- Published by Spandidos Publications in Experimental and Therapeutic Medicine
- Vol. 17 (2), 1128-1131
- https://doi.org/10.3892/etm.2018.6988
Abstract
Erlotinib is a targeted anticancer therapy used for treating epidermal growth factor receptor (EGFR) mutation positive lung cancer in advanced stage as well as for other malignancies. The most common cutaneous side effect of erlotinib, are well documented; however the number of reports regarding cutaneous leukocytoclastic vasculitis (CLCV) are limited. We report a case, a 58-year-old, 60 kg weight, non-smoking woman suffering of lung adenocarcinoma and brain metastases treated with erlotinib monotherapy with 150 mg/day dose, who presents cutaneous leukocytoclastic vasculitis after 8 months of initiating the treatment. The administration of the drug was discontinued and oral prednisolone treatment was introduced at 1 mg/kg body weight dose for two weeks, decreasing the dose with 5 mg, at every 3 days. The treatment was combined with topical potent steroid and antibiotic therapy used once, daily. The lesions cleared within 7 weeks without recurrence. The treatment with erlotinib was restarted after 14 days with a lower dose of 100 mg/day. The skin lesions have not occurred anymore. Unfortunately the evolution was unfavorable, our patient died 3 months after the vasculitis healing, due to the complications of new metastases that occurred. This may indicate the inefficiency of erlotinib. The late onset of 240 days of the vasculitis and the presumed inefficiency of the drug lead to the speculation that the appearance of cutaneous vasculitis could be a worsening clinical marker of the tumor response. This limited number of cases precludes any meaningful interpretation of data about the erlotinib induced cutaneous vasculitis. Further investigations are needed to assess cutaneous vasculitis.Keywords
This publication has 15 references indexed in Scilit:
- A case of necrotizing vasculitis with panniculitis, during sorafenib treatment for hepatocellular carcinoma, appeared in disease progression2014
- Erlotinib induced target-like purpuraDermatology Online Journal, 2014
- Spontaneous reporting of serious cutaneous reactions with protein kinase inhibitorsEuropean Journal of Clinical Pharmacology, 2013
- Cutaneous leukocytoclastic vasculitis due to erlotinib: just an adverse event or also a putative marker of drug efficacy?Cutaneous and Ocular Toxicology, 2013
- Skin Rash could Predict the Response to EGFR Tyrosine Kinase Inhibitor and the Prognosis for Patients with Non-Small Cell Lung Cancer: A Systematic Review and Meta-AnalysisPLOS ONE, 2013
- Successful rechallenge with reduced dose of erlotinib in a patient with lung adenocarcinoma who developed erlotinib-associated leukocytoclastic vasculitis: A case reportOncology Letters, 2012
- [A case of cutaneous vasculitis caused by erlotinib treatment and a review of literature].2011
- Leukocytoclastic Vasculitis after Long-Term Treatment with Sunitinib: A Case ReportCase Reports in Oncology, 2011
- [Henoch-schönlein purpura induced by erlotinib (Tarceva): a case report].2010
- Leukocytoclastic vasculitis during treatment with the oral EGFR tyrosine kinase inhibitor erlotinibAnnals of Oncology, 2007